Skip to main content
. 2021 Sep 27;12(10):881. doi: 10.1038/s41419-021-04156-y

Fig. 1. METTL14-mediated RNA m6A modification were upregulated in the renal cortex of mice with ADR and diabetic nephropathy.

Fig. 1

A The m6A levels of total RNAs in the renal cortex from ADR-treated mice and their corresponding controls quantified by colorimetric ELISA assay (n = 6). B The m6A contents of total RNAs in the renal cortex of diabetic db/db mice and control db/m mice (n = 6). C The relative mRNA levels of major methyltransferases and demethyltransferases in the renal cortex of mice with ADR treatment or normal controls (n = 6). D The relative mRNA levels of major m6A modifying enzymes in the renal cortex of db/db mice compared with control db/m mice (n = 6). E, F Western blot analysis of major methyltransferases and demethyltransferases in the renal cortex of saline- or ADR-treated mice (n = 6). G, H Western blot analysis of major m6A modifying enzymes in the renal cortex of db/db mice and control db/m mice (n = 6). I Representative images and quantification of immunohistochemical staining for METTL14 and WT1 in kidney sections of mice with ADR treatment or normal controls. WT1 were used as podocyte marker. Scale bars, 20 μm (n = 6). J Images and quantification of immunohistochemical staining for METTL14 and WT1 in kidneys from db/m and db/db mice. Scale bars, 20 μm (n = 5). Data are presented as mean ± SEM. **P < 0.01 vs. control group.